Arix Bioscience PLC: Autolus Therapeutics presents positive obe-cel data at the American Society of Hematology (ASH) Annual Meeting 2021
As of the cut-off date of 13 September, 16 patients in the Phase 1b part of the FELIX study had received obe-cel.
- As of the cut-off date of 13 September, 16 patients in the Phase 1b part of the FELIX study had received obe-cel.
- Patient characteristics in the FELIX 1b portion were broadly comparable to those observed in the ALLCAR19 study in r/r adult B-ALL.
- The company expects to present data from the Phase 2 portion of the FELIX study in 2022.
- To listen to the webcast and view the accompanying slide presentation, please go to the events section of Autolus' website.